PRESS RELEASE PR Newswire
Apr. 13, 2022, 06:00 AM
Nuvaxovid™ is the first protein-based COVID-19 vaccine authorized for use in Switzerland
GAITHERSBURG, Md., April 13, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and...
chief executive officer novavax
clinical studies frequency category
country: unknown
important safety information adverse event reporting instructions
myalgia arthralgia injection site tenderness pain fatigue
novavaxconditionalmarketingauthorizationcmanovavax global authorization website
nuvaxovid covid 19 vaccine recombinant adjuvanted
stanley c erck president
two pivotal phase 3 clinical trials
